Biotech News - Ellipsis Biotherapeutics Completes Four Contracts for High ThroughPut Genotyping

Ellipsis Biotherapeutics Completes Four Contracts for High Through-
Put Genotyping Services

DNAPrint Genomics, Inc. (OTCBB:DNAG) today announced that Ellipsis
Biotherapeutics, Inc. will complete a record quarter of revenue
generation from high volume SNP genotyping. A significant portion of
the revenue came from four contracts, including a major American
university, two United Kingdom academic research groups, and one
Toronto based academic hospital program. Ellipsis, acquired by the
Company in November 2005, conducts SNP genotyping using state-of-the-
art technologies. These include single-base primer extension
platforms from Beckman Coulter, Inc. and the GoldenGate(tm) platform
from Illumina, Inc. With a choice of platforms and scales for
performing work, Ellipsis supports companies through the entire
scope of their genotyping efforts. Projects include both high
throughput screening of multiple samples as well as finer mapping to
clarify associations of genetic predisposition in a variety of human
diseases.

"Our goal is to deliver the highest quality SNP genotyping services
to the marketplace, including project development, ongoing
scientific advice and data analysis and interpretation," commented
Dr. Laurence Rubin, founder of Ellipsis. "Ellipsis has completed
these projects on schedule and within budget. Our services have been
instrumental in helping scientists publish their work in respected
scientific journals. In addition to completing large volume contract
services for a variety of projects, we are participating in novel
research programs, which has always been part of the company's
focus," he added.

"We are extremely pleased that Ellipsis Biotherapeutics has met its
first major milestone and has done it with better than budgeted
goals and objectives. We expect that Ellipsis will continue to
contribute to our revenue growth and assist our core pursuit of
pharmaceuticals and diagnostics," said Richard Gabriel, Chief
Executive Officer and President of DNAPrint Genomics, Inc.

For further information on genotyping and other DNA services, please
contact Ellipsis Biotherapeutics at (416) 586-0947.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of
genomics-based products and services in two primary markets:
biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly
owned subsidiary, develops diagnostic tests and theranostic products
(drug/test combinations) using the Company's proprietary ancestry-
informed genetic marker studies combined with proprietary
computational modeling technology. Computational Biology and
Pharmacogenomics services are also offered externally to
biopharmaceutical companies. The Company's first theranostic product
is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for
treatment of anemia in renal dialysis patients (end stage renal
disease). Pre-clinical and clinical development of all the Company's
drug candidates will benefit from simulated pre-trials to better
design actual trials and are targeted to patients with a genetic
profile indicating their propensity to have the best clinical
response. DNAPrint is proud of its continued dedication to
developing and supplying new technological advances in law
enforcement and consumer ancestry heritage interests. Please refer
to www.dnaprint.com for information on law enforcement and consumer
applications which include DNAWITNESS(tm), RETINOME(tm),
ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito
are two tests offered by the Company for additional forensics work.
The results from these tests may be used as identification tools
when a DNA sample is deteriorated or compromised or other DNA
testing fails to yield acceptable results. The Company also performs
contract genotyping and other DNA services through its Ellipsis
Biotherapeutics group in Toronto, Canada.

Forward-Looking Statements

All statements in this press release that are not historical are
forward-looking statements. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, uncertainties
relating to technologies, product development, manufacturing, market
acceptance, cost and pricing of DNAPrint's products, dependence on
collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and
litigation. DNAPrint Genomics, Inc. expressly disclaims any
obligation or undertaking, except as may be required by applicable
law or regulation, to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any
change in DNAPrint's expectations with regard thereto or any change
in events, conditions, or circumstances on which any such statements
are based.

CONTACT: DNAPrint Genomics, Inc.
Richard Gabriel, CEO and President
(941)366-3400

The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/